Register Login

TRANSCODE THERAPEUTICS, INC. (RNAZ)

SymbolRNAZ
NameTRANSCODE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address6 LIBERTY SQUARE,SUITE 2382, BOSTON, Massachusetts, 02109, United States
Telephone+1 857 837-3099
Fax—
Email—
Websitehttps://www.transcodetherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001829635
Description

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The companys lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

Additional info from NASDAQ:
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The companys lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

2026-08-03 20:15

(99% Neutral) TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Regulatory Update

Read more
2026-07-28 20:52

New Form SCHEDULE 13G - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001493152-26-035076 <b>Size:</b> 6 KB

Read more
2026-07-28 20:51

New Form SCHEDULE 13G - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001493152-26-035075 <b>Size:</b> 6 KB

Read more
2026-07-28 20:49

New Form SCHEDULE 13G - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001493152-26-035074 <b>Size:</b> 6 KB

Read more
2026-07-25 01:55

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Read more
2026-07-25 01:36

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Read more
2026-07-23 17:15

New Form SCHEDULE 13D/A - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001104659-26-086266 <b>Size:</b> 11 KB

Read more
2026-07-20 20:15

(99% Neutral) TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Business Combination

Read more
2026-07-20 18:07

New Form 424B3 - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001104659-26-085107 <b>Size:</b> 361 KB

Read more
2026-07-17 20:05

(99% Neutral) TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Regulatory Update

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06260774 Study of TTX-MC138 in Subjects With Advanced Solid Tumors Phase1 Advanced Solid Tumor Active_Not_Recruiting 2024-09-05 2027-02-01 ClinicalTrials.gov
NCT05908773 A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumo… Early_Phase1 Advanced Solid Tumor Completed 2023-04-04 2023-09-18 ClinicalTrials.gov
Total clinical trials: 2
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
TTX-MC138-NODAGA-Cu64 Other Phase EARLY_PHASE1 Advanced Solid Tumor COMPLETED NCT05908773
TTX-MC138 Other Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT06260774
Total products: 2